Sensorion SAS (ALSEN) AI Stock Analysis

• Market Cap: €204.87M
• Dividend Yield: N/A
• Average Volume (3M): 540.27K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: N/A
• EPS Growth: 10.87%
• Country: FR
• Employees: 63
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 514,946,960
• 10 Day Avg. Volume: 740,129
• 30 Day Avg. Volume: 540,266
• PEG Ratio: 0.15
• Price to Book (P/B): 2.50
• Price to Sales (P/S): 27.15
• P/FCF Ratio: -8.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €1.50
• Price Target Upside: 275.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.04
• Revenue Forecast (FY): €13.34M

• Rating: 55 Neutral
• Price Target: €0.38 ▼(-4.00% Downside)
• Action: Reiterated Date: 01/30/26
• Date: Action: Reiterated 01/30/26

The score is held back primarily by ongoing net losses and negative cash flows despite revenue growth and a solid equity base. Technicals are supportive with the stock trading above major moving averages and moderately positive momentum, but valuation remains constrained by loss-making earnings and no dividend support.

Positive Factors

Strong equity position / low leverage

A strong equity base and low leverage provide durable financial flexibility for a clinical-stage biotech. It increases the firm's ability to fund costly trials, pursue partnerships, and absorb setbacks without immediate solvency pressure, lengthening runway versus highly leveraged peers.

Revenue growth and positive gross margin

Reported revenue growth coupled with a positive gross profit margin indicates early commercial or reimbursed activity that covers direct costs. This suggests the company can scale revenue contributions as programs mature, improving long-term unit economics if clinical advances continue.

Multiple non-sales funding pathways

Reliance on collaborations, licensing, grants and equity is a typical, durable biotech funding model. It enables risk-sharing, milestone monetization and non-dilutive support, allowing Sensorion to advance programs without immediate product sales and to de-risk clinical assets for partners.

Negative Factors

Persistent net losses

Sustained net losses and negative operating cash flow weaken capital resilience over time. For a clinical-stage firm this raises funding frequency and dilution risk, and implies management must secure periodic financing or partnerships before products generate predictable revenues.

High reliance on equity financing

Material dependence on equity raises to fund operations is dilutive and ties future program progress to capital market access. If market conditions tighten or investor appetite wanes, the company could face financing squeezes that delay trials or force less-favorable partnership terms.

No marketed products / no recurring revenue

Absence of marketed products means long lead times to sustainable revenue and binary clinical/regulatory outcomes determine future cash generation. This structural lack of recurring income increases operational risk and places heavy reliance on successful trial outcomes or partner commercialization.

Sensorion SAS Business Overview & Revenue Model

Company Description

Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.

How the Company Makes Money

Sensorion SAS generates revenue through multiple streams, primarily from the development and commercialization of its therapeutic products. The company engages in partnerships and collaborations with pharmaceutical firms and research institutions, which often involve upfront payments, milestone payments, and royalties on future sales of products developed through these alliances. Additionally, Sensorion may receive funding through grants and public subsidies aimed at supporting medical research and development in the field of hearing disorders. These strategic partnerships and funding opportunities contribute significantly to the company's financial stability and growth potential.

Sensorion SAS Financial Statement Overview

Summary

Revenue is growing and the balance sheet shows a healthy equity position with low leverage, but the company continues to post significant net losses and negative operating/free cash flow, increasing execution and funding risk.

Income Statement

Sensorion SAS has experienced revenue growth, but profitability remains a concern. While total revenue increased from the previous year, the company continues to operate at a significant net loss. The gross profit margin is positive, indicating effective revenue management, but negative EBIT and EBITDA margins reflect high operational costs. The consistent net loss indicates a need for improved cost management and revenue enhancement strategies.

Balance Sheet

The company maintains a strong equity position with a low debt-to-equity ratio, suggesting financial stability. Stockholders' equity has improved significantly, indicating investor confidence and capital raising success. However, the persistent net losses continue to erode equity value. The equity ratio is healthy, reflecting a strong capital structure, but ongoing losses could pose risks if not addressed.

Cash Flow

Sensorion SAS exhibits a challenging cash flow position with negative operating and free cash flows. Despite generating significant financing cash flow, largely from equity raises, the company has been unable to generate positive free cash flow. The free cash flow to net income ratio remains negative, reflecting ongoing operational challenges. A focus on improving operating cash flow is essential for long-term financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.84M	6.65M	5.70M	4.93M	4.26M	2.35M
Gross Profit	5.84M	6.65M	3.79M	4.16M	3.75M	1.94M
EBITDA	-30.40M	-27.58M	-21.33M	-22.44M	-17.46M	-10.26M
Net Income	-28.09M	-25.97M	-22.06M	-23.21M	-15.14M	-8.98M
Balance Sheet
Total Assets	73.34M	89.28M	46.50M	38.93M	59.02M	67.87M
Cash, Cash Equivalents and Short-Term Investments	57.06M	76.98M	36.97M	26.20M	50.00M	62.17M
Total Debt	1.55M	2.20M	2.87M	3.76M	3.99M	3.88M
Total Liabilities	16.36M	17.14M	13.23M	17.06M	15.03M	9.52M
Stockholders Equity	56.98M	72.14M	33.27M	21.87M	43.98M	58.35M
Cash Flow
Free Cash Flow	-28.83M	-22.45M	-21.94M	-22.92M	-11.81M	-5.48M
Operating Cash Flow	-28.28M	-21.33M	-21.07M	-21.41M	-10.77M	-5.31M
Investing Cash Flow	-11.15M	-11.13M	-381.06K	-1.54M	-1.07M	-164.93K
Financing Cash Flow	-1.20M	62.26M	32.20M	-820.68K	-715.07K	37.23M

Sensorion SAS Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALSEN, the sentiment is Positive. The current price of 0.4 is above the 20-day moving average (MA) of 0.33, above the 50-day MA of 0.32, and above the 200-day MA of 0.34, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 67.88 is Neutral, neither overbought nor oversold. The STOCH value of 90.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALSEN.

Sensorion SAS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALSEN	55 Neutral	€204.87M	-4.26	-40.00%	―	―	10.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NANO	49 Neutral	€1.31B	―	―	―	―	―
OSE	49 Neutral	€95.33M	-2.68	-52.76%	―	-96.92%	-175.84%
MAAT	48 Neutral	€134.03M	-3.32	―	―	52.55%	-5.97%
IPH	47 Neutral	€134.59M	-2.61	-271.32%	―	-75.86%	-30.54%
TNG	43 Neutral	€245.42M	-3.22	―	―	111.76%	-22.45%